MBX Biosciences, Inc.
$33.78
▲
2.17%
2026-04-21 08:04:00
mbxbio.com
NMS: MBX
Explore MBX Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.6 B
Current Price
$33.78
52W High / Low
$44.89 / $7.09
Stock P/E
—
Book Value
$8.22
Dividend Yield
—
ROCE
-26.53%
ROE
-27.76%
Face Value
—
EPS
$-2.38
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
63
Beta
—
Debt / Equity
0.16
Current Ratio
24.62
Quick Ratio
24.62
Forward P/E
-7.63
Price / Sales
—
Enterprise Value
$1.1 B
EV / EBITDA
-11.24
EV / Revenue
—
Rating
Strong Buy
Target Price
$62.55
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Tenax Therapeutics, Inc. | $14.1 | — | $247.99 M | — | -58.09% | -55.64% | $18.38 / $4.63 | $2.29 |
| 2. | BioAtla, Inc. | $5.69 | — | $7.61 M | — | 732.7% | 543.76% | $71.5 / $3.92 | $-0.6 |
| 3. | Vyome Holdings, Inc. | $2.35 | — | $16.49 M | — | -73.02% | 1053.07% | $56.36 / $1.75 | $0.41 |
| 4. | Arcutis Biotherapeutics, Inc. | $24.47 | — | $3.04 B | — | -4.03% | -9.3% | $31.77 / $12.42 | $1.54 |
| 5. | BioRestorative Therapies, Inc. | $0.26 | — | $6.72 M | — | -4386.1% | -3.2% | $2.04 / $0.19 | $0.04 |
| 6. | Aditxt, Inc. | $0.35 | — | $0.39 M | — | -318.91% | -6.99% | $2,594.48 / $0.39 | $-151.87 |
| 7. | Spyre Therapeutics, Inc. | $73.39 | — | $5.76 B | — | -30.53% | -25.17% | $75 / $12.25 | $7.16 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -25.8 M | -23.93 M | -21.8 M | -26.53 M | -18.61 M |
| Net Profit | -22.06 M | -21.62 M | -19.41 M | -23.88 M | -15.59 M |
| EPS in Rs | -0.46 | -0.46 | -0.41 | -0.5 | -0.33 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -98.06 M | -68.19 M | -35.31 M | -25.16 M |
| Net Profit | -86.97 M | -61.92 M | -32.56 M | -26.14 M |
| EPS in Rs | -1.83 | -1.3 | -0.69 | -0.55 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 385.14 M | 268.54 M | 84.18 M | 45.09 M |
| Total Liabilities | 15.92 M | 11.09 M | 156.65 M | 87.7 M |
| Equity | 369.22 M | 257.44 M | -72.47 M | -42.6 M |
| Current Assets | 381.54 M | 267.29 M | 83.47 M | 44.21 M |
| Current Liabilities | 15.49 M | 11.05 M | 3.93 M | 3.43 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -79.95 M | -54.68 M | -31.98 M | -23.12 M |
| Investing CF | -83.7 M | -160.59 M | -30.93 M | -11.41 M |
| Financing CF | 189.59 M | 234.1 M | 69.22 M | 46.06 M |
| Free CF | -81.88 M | -55.55 M | -32.11 M | -23.56 M |
| Capex | -1.93 M | -0.87 M | -0.13 M | -0.44 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -40.45% | -90.16% | -24.6% | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.